Business
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID® and ~$700 million for DAYBUE® - Top-line results from
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\n- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID® and ~$700 million for DAYBUE®\n\n\n- Top-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP-204) in Alzheimer’s disease psychosis anticipated between August and October 2026\n\n\n- U.S. launch of DAYBUE® STIX on a limited basis begins Q1 2026, with full launch planned Q2 2026\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.\n\n\n“2026 marks a pivotal year for Acadia as we advance our strategy built for sustained growth and pipeline advancement,” said Catherine Owen Adams, Chief Executive Officer. “With approximately $1.7 billion in global projected net sales by 2028, our commercial engine anchored by NUPLAZID and DAYBUE, continues to gain momentum. The introduction of DAYBUE STIX in the U.S. represents an exciting opportunity to deliver a more flexible option for patients and caregivers, further strengthening our leadership position in Rett syndrome care. Coupled with the anticipated Phase 2 readout of remlifanserin in Alzheimer’s disease psychosis later this year, Acadia is well-positioned to capture significant value across both our commercial portfolio and pipeline.”\n\n\nKey Milestones\n\n\n\nStrong commercial growth outlook projecting approximately $1.7 billion in net sales in 2028, with NUPLAZID contributing ~$1 billion and DAYBUE ~$700 million.\n\n\n\n\nTop-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP‑204) in Alzheimer’s disease psychosis (ADP), expected in the August to October 2026 timeframe.\n\n\n\n\nRemlifanserin expected to account for approximately $4 billion of the $11 billion unadjusted full peak sales opportunity represented by its current pipeline, attributable to remlifanserin in both Alzheimer’s disease psychosis and Lewy body dementia psychosis.\n\n\n\n\nDAYBUE STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation approved by the U.S. FDA on December 12, 2025, for the treatment of Rett syndrome in adult...